Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.60 |
| ▸ | THRA | P10827 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LIG1 | P18858 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11240569 | 0.86 | THRB (0.63) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL146450 | 0.84 | THRB (0.70) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL6219545 | 0.84 | THRB (0.61) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL2855272 | 0.83 | THRB (0.60) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL311912 | 0.83 | THRA (0.60) | THRBTHRAKDM4EALDH1A1TSHR | |
| SCHEMBL28620207 | 0.83 | THRB (0.60) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL4596410 | 0.82 | THRB (0.59) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL10523686 | 0.82 | THRB (0.75) | THRBTHRATYMSPTGS2 | |
| SCHEMBL27461371 | 0.81 | THRB (0.58) | THRBTHRAKDM4EMAPTHPGD | |
| SCHEMBL29413361 | 0.81 | THRB (0.56) | THRBTHRAKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4324825-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Best Pathway Management Consulting Center (Limited Partnership) (CN) | 2024-02-21 | — | — | EP | disclosed |
| CN-116903581-A | SHP2/HDAC double-target inhibitor and preparation method and application thereof | 山东大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116589464-A | Pyrimidine ring compound, preparation method and application thereof | 上海科技大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-115215823-A | FXR (FXR) regulator and preparation method, pharmaceutical composition and application thereof | 青岛睿吉医疗技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-108137518-B | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-08-31 | — | — | CN | disclosed |
| CN-113166081-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110551067-B | Multi-target tacrine derivative and preparation method and application thereof | 山东大学 | 2020-09-08 | — | — | CN | disclosed |
| CN-110551067-A | Multi-target tacrine derivative and preparation method and application thereof | UNIV SHANDONG | 2019-12-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | SLC10A1, NR1H4, FXR1 | THRB 427/4885THRA 610/4885KDM4E 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.